Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Up 427.1% in December

Eterna Therapeutics Inc. (NASDAQ:ERNA) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 606,200 shares, an increase of 427.1% from the November 30th total of 115,000 shares. Based on an average daily trading volume, of 712,600 shares, the short-interest ratio is presently 0.9 days. Approximately 1.2% of the shares of the company are short sold.

Eterna Therapeutics Trading Up 13.7 %

Eterna Therapeutics stock traded up $0.03 during mid-day trading on Thursday, reaching $0.28. The company’s stock had a trading volume of 604,819 shares, compared to its average volume of 195,553. Eterna Therapeutics has a twelve month low of $0.22 and a twelve month high of $2.63. The business has a 50 day moving average price of $0.67 and a 200-day moving average price of $1.31. The firm has a market cap of $1.53 million, a price-to-earnings ratio of -0.03 and a beta of 4.18.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.